Combining optimised expression and gene integration to deliver higher titers, faster cell line development and stable manufacturing, without changing your workflow.
Combining optimised expression and gene integration to deliver higher titers, faster cell line development and stable manufacturing, without changing your workflow.
Increases output at every stage of cell line development, from transfection through to stable production.
At the platform level, this is driven by a significant increase in protein expression per integrated gene copy, resulting from increased mRNA levels, more protein per transcript and more consistent expression following integration.
Applicable across monoclonal antibodies, biosimilars, Fc fusions and complex or difficult-to-express biologics.
Efficient transposase-mediated integration integrates complete genes at multiple genomic loci, resulting in high expression per integrated gene copy and supporting the rapid generation of high-producing stable pools and clones.
A higher proportion of productive integration events leads to more uniform and reliable cell populations.
Boosting expression at every stage
Increases protein production by enhancing both transcription and translation.
The architecture behind enhanced expression
The 2G UNic vector technology incorporates optimised regulatory elements that drive strong transcription and efficient translation, increasing protein output per gene copy.
Achieve 2–5× higher expression across multiple formats, including challenging biologics, with titers >10 g/L.
Reduce screening and move more quickly from transfection to high-producing stable cell lines.
Deliver consistent, long-term expression to support reliable process performance and scale-up.
Shifts clone populations from predominantly low producers to consistently high-producing clones
Productivity gains are observed across multiple CHO host systems and selection platforms, including antibiotic, DHFR and GS-based systems.
Demonstrated across:
Applicable to:
In CHOZN GS systems, improved integration efficiency and cell viability accelerate recovery and enable earlier establishment of stable, high-producing pools.
Save over one week generating pools
In a biosimilar program, increased productivity at the pool level translates directly into stronger clone performance, reducing the effort required to identify high-producing clones.
Supports targeted integration workflows by improving expression per integrated copy.
Flexible adoption within your existing workflow
2G UNic vector technology improves expression at the vector level, increasing output when combined with established transposon-based integration systems.
Increased titers across pools and clones
Accelerated recovery and clone selection
Consistent performance across populations
Full platform or modular integration
Compatible with existing workflows
Additional datasets across molecules, host systems and development stages, including titers exceeding 10 g/L in CHO systems.
